These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Methodological approaches to the assessment of cognitive symptoms during psychopharmacotherapy]. Tsygankov BD; Khananova AN Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(10):66-71. PubMed ID: 21510452 [No Abstract] [Full Text] [Related]
7. Medicine. What are the right targets for psychopharmacology? Hyman SE; Fenton WS Science; 2003 Jan; 299(5605):350-1. PubMed ID: 12532001 [No Abstract] [Full Text] [Related]
9. Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia. Keefe RS; Meltzer HA; Dgetluck N; Gawryl M; Koenig G; Moebius HJ; Lombardo I; Hilt DC Neuropsychopharmacology; 2015 Dec; 40(13):3053-60. PubMed ID: 26089183 [TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase Targets for Cognitive Dysfunction and Schizophrenia--a New York Academy of Sciences Meeting. Zhang HT IDrugs; 2010 Mar; 13(3):166-8. PubMed ID: 20191432 [TBL] [Abstract][Full Text] [Related]
11. Effects of atomoxetine on cognitive function and cigarette smoking in schizophrenia. Sacco KA; Creeden C; Reutenauer EL; Vessicchio JC; Weinberger AH; George TP Schizophr Res; 2009 Feb; 107(2-3):332-3. PubMed ID: 18995989 [No Abstract] [Full Text] [Related]
12. Clinical symptoms, mainly negative symptoms, mediate the influence of neurocognition and social cognition on functional outcome of schizophrenia. Lin CH; Huang CL; Chang YC; Chen PW; Lin CY; Tsai GE; Lane HY Schizophr Res; 2013 May; 146(1-3):231-7. PubMed ID: 23478155 [TBL] [Abstract][Full Text] [Related]
13. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Keefe RS; Fox KH; Harvey PD; Cucchiaro J; Siu C; Loebel A Schizophr Res; 2011 Feb; 125(2-3):161-8. PubMed ID: 21075600 [TBL] [Abstract][Full Text] [Related]
14. Psychotropic effects of ritanserin, a selective S2 antagonist: an open study. Strauss WH; Klieser E Eur Neuropsychopharmacol; 1991 May; 1(2):101-5. PubMed ID: 1821698 [TBL] [Abstract][Full Text] [Related]
15. Important steps in the development of cognitive-enhancing drugs in schizophrenia. Buchanan RW Am J Psychiatry; 2006 Nov; 163(11):1867-9. PubMed ID: 17074932 [No Abstract] [Full Text] [Related]
16. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Kern RS; Nuechterlein KH; Green MF; Baade LE; Fenton WS; Gold JM; Keefe RS; Mesholam-Gately R; Mintz J; Seidman LJ; Stover E; Marder SR Am J Psychiatry; 2008 Feb; 165(2):214-20. PubMed ID: 18172018 [TBL] [Abstract][Full Text] [Related]
20. Cognitive neuroscience and schizophrenia: translational research in need of a translator. Cohen JD; Insel TR Biol Psychiatry; 2008 Jul; 64(1):2-3. PubMed ID: 18549873 [No Abstract] [Full Text] [Related] [Next] [New Search]